- Taiwan Oyi peptide Co. Ltd
- China
- Product Name: (LEU31,PRO34)-PEPTIDE YY (HUMAN) TRIFLUOROACETATE SALT
- Price: $Inquiry/1mg $Inquiry/100kg
- Purity: 98.0%
- Stocking Period: 1 Day
- Contact: Vinnie
179986-95-9
179986-95-9 structure
- Name: (Leu31,Pro34)-Peptide YY (human) trifluoroacetate salt
- Chemical Name: (4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-2-[(2S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-1-[[(1S,2R)-1-[[(1S)-1-[(2S)-2-[[(1S)-1-[[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-carboxy-propyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]amino]-4-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methyl-pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxy-butanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxo-pentanoic acid
- CAS Number: 179986-95-9
- Molecular Formula: C195H296N54O56
- Molecular Weight:
- Catalog: Signaling Pathways GPCR/G Protein Neuropeptide Y Receptor
- Create Date: 2018-06-19 13:15:54
- Modify Date: 2024-01-06 14:04:50
-
(Leu31,Pro34)-Peptide YY (human) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y1 agonist with a KD of 1.0 nM[1].
| Name | (4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-2-[(2S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-1-[[(1S,2R)-1-[[(1S)-1-[(2S)-2-[[(1S)-1-[[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-carboxy-propyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]amino]-4-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methyl-pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxy-butanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxo-pentanoic acid |
|---|
| Description | (Leu31,Pro34)-Peptide YY (human) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y1 agonist with a KD of 1.0 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
NPY Y1 receptor:1.0 nM (Kd) NPY Y2 receptor:670 nM (Kd) |
| In Vitro | (Leu31,Pro34)-Peptide YY 在大鼠额顶叶皮质膜制剂 (Y1 富集组织) 和兔大隐静脉 (Y1 体外生物测定) 中表现出高亲和力 (nM)，但在 Y2 富集制剂 (大鼠海马) 中仅表现出低亲和力[1]。 |
| In Vivo | (Leu31,Pro34)-Peptide YY (0.1-1 nmol/day; ICV; 14 days) 对大鼠有抗焦虑和抗抑郁作用[2]。 Animal Model: Male Sprague Dawley rats weighing 150-170 g, OBX/Sham model[2] Dosage: 0.1, 0.3 and 1 nmol/day Administration: ICV, for 14 days Result: Significantly decreased hyperlocomotion and immobility time in OBX animals. Reversed the deficit in social contacts in OBX animals. Reduced grooming behavior in sham animals. |
| References |
| Molecular Formula | C195H296N54O56 |
|---|